Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	250.01	40.91	37.42	171.13	104.39
Revenue Growth (YoY)	511.16%	9.33%	-78.14%	63.93%	1270.14%
Gross Profit	250.01	40.91	37.42	171.13	104.39
Selling, General & Admin	35.82	30.98	37.25	34.99	36.34
Research & Development	92.17	60.76	73.79	108.75	119.74
Operating Expenses	127.99	91.74	111.03	143.74	156.07
Operating Income	122.01	-50.84	-73.62	27.38	-51.68
Interest Expense / Income	-11.72	-1.79	0.39	-1.66	-6.46
Other Expense / Income	-0	-2.65	-2.81	-7.7	-1.63
Pretax Income	133.74	-46.39	-71.2	36.74	-43.6
Income Tax	1.41	0.02	0	0	0
Net Income	132.33	-46.41	-71.2	36.74	-43.6
Shares Outstanding (Basic)	43	38	38	37	36
Shares Outstanding (Diluted)	45	38	38	37	36
Shares Change	16.20%	1.83%	0.86%	4.04%	11.95%
EPS (Basic)	3.08	-1.21	-1.89	0.99	-1.21
EPS (Diluted)	2.97	-1.21	-1.89	0.98	-1.21
Free Cash Flow	74.66	-15	-55.13	-108.81	41.12
Free Cash Flow Per Share	1.74	-0.39	-1.46	-2.93	1.15
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	48.80%	-124.27%	-196.76%	16.00%	-49.51%
Profit Margin	52.93%	-113.45%	-190.29%	21.47%	-41.76%
Free Cash Flow Margin	29.86%	-36.67%	-147.36%	-63.59%	39.39%
Effective Tax Rate	1.05%	-	-	-	-
EBITDA	126.46	-41.99	-65.64	38.9	-47.29
EBITDA Margin	50.58%	-102.65%	-175.44%	22.73%	-45.30%
Depreciation & Amortization	4.44	6.19	5.17	3.82	2.77
EBIT	122.02	-48.18	-70.81	35.08	-50.05
EBIT Margin	48.81%	-117.79%	-189.25%	20.50%	-47.95%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).